TWI455716B - 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途 - Google Patents

選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途 Download PDF

Info

Publication number
TWI455716B
TWI455716B TW096139544A TW96139544A TWI455716B TW I455716 B TWI455716 B TW I455716B TW 096139544 A TW096139544 A TW 096139544A TW 96139544 A TW96139544 A TW 96139544A TW I455716 B TWI455716 B TW I455716B
Authority
TW
Taiwan
Prior art keywords
sprm
administration
period
day
application
Prior art date
Application number
TW096139544A
Other languages
English (en)
Other versions
TW200822931A (en
Inventor
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of TW200822931A publication Critical patent/TW200822931A/zh
Application granted granted Critical
Publication of TWI455716B publication Critical patent/TWI455716B/zh

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (11)

  1. 一種選自CDB-4124(21-甲氧基-17α -乙醯氧基-11β -(4-N,N-二甲胺基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮)及17α -乙醯氧基-11β -(4-N,N-二甲胺基苯基)-19-去甲孕甾(norpregna)-4,9-二烯-3,20-二酮之選擇性黃體激素受體調節劑(SPRM)用於製造用於根據間歇投服治療方案治療女性慢性雌激素依賴性子宮組織過度增生同時避免與子宮內膜停滯(stagnant endometrium)有關的不良反應之藥物的用途，該間歇投服治療方案包含於投服期間投服2至80mg之該SPRM，在該投服期間，該SPRM係連續一至六個月每日或每隔一日投服；接著中斷該投服，此期間足夠使該女性經歷月經，該期間短於該投服期間；接著連續一至六個月每日或每隔一日投服治療2至80mg之該SPRM；接著中斷該投服，此期間足夠使該女性經歷月經，該期間短於該投服期間，並只要需要時重複此投服及停藥，以達到治療該病症。
  2. 如申請專利範圍第1項之用途，其中該SPRM於每次投服期間係每日投服。
  3. 如申請專利範圍第1項之用途，其中各停藥期係至少32天。
  4. 如申請專利範圍第1項之用途，其中該女性在該至少一中斷期間投服誘發月經之有效量的黃體製劑(progestin)。
  5. 如申請專利範圍第4項之用途，其中該女性投服 之黃體製劑係選自：甲羥黃體激素(medroxyprogesterone)、羥基黃體激素(hydroxyprogesterone)及黃體激素。
  6. 如申請專利範圍第1項之用途，其中該SPRM是CDB-4124(21-甲氧基-17α -乙醯氧基-11β -(4-N,N-二甲胺基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮)。
  7. 如申請專利範圍第1項之用途，其中該藥物之投服劑量係從約26mg/天至約80mg/天。
  8. 如申請專利範圍第7項之用途，其中該藥物之投服劑量係約50mg/天。
  9. 如申請專利範圍第1項之用途，其中投服期間係從約1至約6個月。
  10. 如申請專利範圍第1項之用途，其中該SPRM是17α-乙醯氧基-11β-(4-N,N-二甲胺基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮。
  11. 如申請專利範圍第1項之用途，其中該SPRM係連續至少30天每日或每隔一日投服；接著中斷該投服，此期間足夠使該女性經歷月經，該期間短於該投服期間；接著連續至少30天每日或每隔一日投服治療有效量之SPRM；接著中斷該投服，此期間足夠使該女性經歷月經，該期間短於該投服期間，並只要需要時重複此投服及停藥，以達到治療該病症。
TW096139544A 2006-10-24 2007-10-22 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途 TWI455716B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86263206P 2006-10-24 2006-10-24

Publications (2)

Publication Number Publication Date
TW200822931A TW200822931A (en) 2008-06-01
TWI455716B true TWI455716B (zh) 2014-10-11

Family

ID=41095733

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096139544A TWI455716B (zh) 2006-10-24 2007-10-22 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途

Country Status (4)

Country Link
CN (2) CN104997789A (zh)
RS (1) RS56491B1 (zh)
TW (1) TWI455716B (zh)
UA (1) UA98124C2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105963687A (zh) * 2016-04-27 2016-09-28 张金凤 一种用于治疗慢性盆腔疼痛的复方制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO2006010097A2 (en) * 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO2006010097A2 (en) * 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators

Also Published As

Publication number Publication date
TW200822931A (en) 2008-06-01
UA98124C2 (ru) 2012-04-25
CN101528764A (zh) 2009-09-09
CN104997789A (zh) 2015-10-28
RS56491B1 (sr) 2018-01-31

Similar Documents

Publication Publication Date Title
KR20060126671A (ko) 에스트로겐 및 프로게스틴을 포함하는 연장 사용 조합제
JP2013523683A5 (zh)
RU2011146058A (ru) Способ контрацепции, используемый по мере необходимости
CN101626760A (zh) 利用递增剂量长周期给药方案进行激素治疗的方法
JPH08510993A (ja) ホルモン補充方法
KR20010081087A (ko) 3 단계 경구 피임제
KR20110045065A (ko) 월경 억제, 피임 및 호르몬 대체 요법을 위한 약제 및 이를 투여하는 방법
Rasheed et al. A review of natural steroids and their applications
WO2003077924A1 (en) Continuous sulfatase inhibiting progestogen hormone replacement therapy
JP2018533542A (ja) 月経困難症および月経痛の管理のための方法
ZA200404249B (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US12005138B2 (en) Treatment of endometriosis by intravaginal administration of a low dose of a selective progesterone receptor modulator (SPRM), anti-progestin, or anti-progestational agent
ES2279515T3 (es) Antagonistas competitivos de la progesterona para el control de la fertilidad femenina, orientado a las necesidades de uso.
US9545411B2 (en) Methods and compositions for treating progesterone-dependent conditions
EP1699464A1 (en) Menstrual cycle control and improvement of conception rates in females
Stevenson Optimising delivery systems for HRT
TWI455716B (zh) 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
JP2013047269A (ja) 経口避妊薬の形での機能不全子宮出血の経口治療のためへの吉草酸エストラジオール又はエストラジオールとジエノゲストとの使用
ES2320662T3 (es) Hormonoterapia restitutiva y tratamiento para la depresion con dienogest.
Mansour Use of the new progestogens in contraception and gynaecology
Bruni et al. Contraception and Family Planning: New Aspects Related to the Therapeutic Possibilities
Hernández-Valencia et al. Symptomatic changes in postmenopause with different methods of hormonal therapy
Dimitrijevic Drug Methods for Arteficial Termination of Unwanted Pregnancy
BE1027858A1 (fr) Composition pharmaceutique pour la contraception chez la femme
Yuzpe et al. Postcoital contraception

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees